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Vitiligo is an acquired dermatological disease frequently associated with autoimmune thyroid disorders. Several theories have been
proposed so far to unravel the complex vitiligo pathogenesis. Currently, the autocytotoxic and the autoimmune theories are the
most accredited hypothesis, since they are sustained by several important clinical and experimental evidences. A growing body
of evidences shows that autoimmunity and oxidative stress strictly interact to finally determine melanocyte loss. In this scenario,
associated thyroid autoimmunitymight play an active and important role in triggering andmaintaining the depigmentation process
of vitiligo.
1. Introduction
Vitiligo is an acquired dermatological disorder characterized
by circumscribed depigmented macules due to the loss of
functional melanocytes in the epidermis [1].This pigmentary
disease is frequently associated with some autoimmune
comorbidities and particularly with autoimmune thyroid
disorders (ATD) [2, 3].
Several theories have been proposed so far to dis-
close vitiligo pathogenesis, such as the autoimmune the-
ory [4], the autocytotoxic theory [5, 6], the neural theory
[7], the “impaired epidermal cytokine” theory [8–10], the
melanocythorragic hypothesis [11], and the recent inflamma-
tory theory [12], which are currently considered as synergistic
in determining the disease [5].
Among the abovementioned theories however, the auto-
cytotoxic and the autoimmune theories are at present the
most accredited, since they are sustained by several impor-
tant clinical and experimental evidences. Current litera-
ture reports several evidences suggesting a strict interplay
between oxidative stress and immune system, able to trigger
and maintain vitiligo depigmentation process and the even-
tually associated ATD [13].
This review focuses on the most important evidences
regarding the role of autoimmunity and oxidative stress,
and their interactions, in vitiligo and autoimmune thyroid
disorders. Moreover, we suggest a pathogenetic scenario in
which the abovementioned autoimmune diseases coexist and
sustain each other in a deleterious vicious cycle.
2. Vitiligo and Oxidative Stress
In the last decades, a lot of studies suggested that an hyper-
sensitivity to oxidative stress has a crucial role in determining
melanocyte degeneration [14]. Vitiligo skin of active phase
patients has been demonstrated to display high epidermal
levels of reactive oxygen species (ROS), primarily represented
by hydrogen peroxide (H
2
O
2
) and peroxynitrite [15, 16].
These alterations are the result of a local and systemic imbal-
ance in enzymatic and nonenzymatic antioxidant systems
[17].
Indeed, an abnormal function of the metabolic system of
biopterins, leading to high levels of the tetrahydrobiopterin
(6BH
4
) and its isomer 7BH
4
, has been demonstrated in
vitiligo epidermis [18, 19]. Biopterins act as inhibitors of the
enzymes involved in melanogenesis (namely, phenylalanine
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hydroxylase and tyrosinase) and stimulate the formation of
H
2
O
2
[10–22].
In addition, low levels of enzyme catalase [23–25], an
antioxidant enzyme that catalyzes the conversion of hydrogen
peroxide in water plus oxygen, and other antioxidant agents
such as glutathione peroxidase, glucose-6-phosphate dehy-
drogenase, superoxide dismutase, and vitamins C and E have
been detected both in the epidermis or in the serumof vitiligo
patients [15, 25–27], thus suggesting a systemic redox defect
in this disease.
An increase of ROS might also be the consequence of an
impaired mitochondrial functioning. Indeed, ultrastructural
alterations in keratinocytes mitochondria, such as swelling
of their membranes and a rearrangement of the cristae,
have been demonstrated in the epidermis of vitiligo skin
biopsies [28]. Such structural defects directly correlate with a
consequent impaired mitochondrial activity, thus leading to
an increased generation of reactive oxygen species [28].
As a consequence, local and systemic high levels of H
2
O
2
are able to alter calcium homeostasis, consequently perturb-
ing the uptake of L-phenylalanine, the amino-acid precursor
of tyrosine in melanocytes [29]. In addition, ROS are able
to oxidize and inhibit the activity of proopiomelanocortin-
derived bioactive peptides ACTH and a-MSH that have
crucial role in maintaining efficient melanogenesis, since
their release activates a cascade of intracellular signals leading
to an upregulation of key enzymes for melanin synthesis,
such as tyrosinase and tyrosinase-related proteins TYRP-1
and TYRP-2 (or dopachrome tautomerase, DCT) [30].
ROS accumulation is also able to induce lipid perox-
idation, DNA damage, an increased production of proin-
flammatory and antimelanogenic cytokines, and the loss of
functionality of enzymes playing a key role in melanogenesis
[31].
Most of the unfavourable effects of H
2
O
2
accumula-
tion are more frequently observed in keratinocytes and
melanocytes derived from perilesional skin, thus suggesting
a pivotal role of such area in initiating the depigmentation
process.
Moreover, recent studies pointed out the importance of
the Nrf2-antioxidant response element (ARE) pathway in
regulating vitiligo skin homeostasis under oxidative stress
and gave the possibility to explain the hypersensitivity of
vitiligo melanocytes to oxidative damage [32–34]. The Nrf2-
antioxidant response element (ARE) is indeed a major
antioxidant pathway, since it regulates the transcription of
stress-related cytoprotective genes, thus protecting cells from
oxidative stress and chemical-induced cellular damage. It
has been demonstrated that the Nrf2-ARE pathway protects
human melanocytes from H
2
O
2
-damage through the induc-
tion of downstream antioxidant genes [33], such as heme
oxygenase-1 (HO-1). A recent in vitro study showed that
vitiligo melanocytes have reduced Nrf2 nuclear translocation
and transcriptional activity, which lead to decreased HO-1
expression and aberrant redox balance. Accordingly, authors
demonstrated in a clinical setting that serum levels of HO-
1 were significantly decreased in vitiligo patients, when
compared with healthy controls [34].
Also the Forkhead box class O (FOXO) proteins, a class
of transcription factors whose activation leads to the indu-
ction of gene codifying for antioxidant proteins, seem to be
involved in vitiligo antioxidant impairments [35]. Recently
some authors reported a significant association between a
specific polymorphism of FOXO3a gene in active vitiligo
patients, together with decreased levels of FOXO3a protein,
compared to a control group [35].
Finally, a further theory sustaining the pathogenic role of
oxidative stress in vitiligo, called the haptenation theory, has
been proposed [36]. According to this hypothesis, high levels
of hydrogen peroxide (H
2
O
2
) might lead to increased levels
of ortho-phenols surrogate substrates of tyrosinase. Authors
sustain that vitiligo tyrosinase, due to a genetically controlled
polymorphism, could be able to accept the abovementioned
substrates, which covalently bind to the enzyme after con-
version to reactive ortho-quinone [36]. This process might
modify tyrosinase into a neoantigen possibly recognized by
the immune system, thus triggering the autoimmune reaction
at the basis of the depigmentation process observed in vitiligo
[36].
According to all the above reported evidences, in the last
decades, some clinical studies showed the beneficial effects of
the use of oral and topical antioxidants in association with
conventional vitiligo treatment [37–40], thus suggesting the
importance to restore the defective antioxidant system in
vitiligo patients.
3. Vitiligo and Autoimmunity
With regard to the autoimmune theory, it is generally
accepted that autoimmunity is strongly implicated in the
development of the vitiligo [41], so that this pigmentary
disorder is widely considered as autoimmune disease. This
theory is sustained by several epidemiological, clinical, and
laboratory studies [1, 4, 42, 43]. Elevated organ and non-
organ-specific autoantibodies levels have been reported in
the serum of vitiligo patients [43]. The frequency of such
autoantibodies is variable according to different studies con-
ducted so far [1, 3, 43–46], and their role in vitiligo patients
is still quite unknown, mostly if patients positive for such
autoantibodies do not display clinical signs of autoimmune
associated diseases. However, the finding of elevated organ-
specific autoantibodies in vitiligo patients might represent a
predictive marker of future overt autoimmune disorders [4].
The involvement of the humoral response in vitiligo is
documented by the finding of circulating autoantibodies
directed towards melanocytic antigens [47–50], whose levels
correlate with disease activity [47]. Such autoantibodies,
pertaining to class G immunoglobulins, have been found also
in the basal layer of lesional vitiligo epidermis, in association
with complement component 3 (C3) deposits [48]. Major
melanocytic antigens are the proteins tyrosinase, tyrosinase-
related protein-1 (TRP-1), TRP-2, Pmel17 (also called gp100),
the transcriptional factors SOX 9 and SOX 10, and the type
1 membrane receptor for melanin-concentrating hormone
(MCH-R1) [49–52].
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Peripheral blood of patients with vitiligo is also character-
ized by high frequencies of melanocyte-reactive cytotoxic T
cells [39], able to release type B granzyme, perforin, and IFN𝛾
[53, 54], while perilesional T-cell infiltration can be found
in vitiligo epidermis [54]. It has been demonstrated that
perilesional lymphocytic infiltrate is constituted by T cells
appearing as skin-homing, polarized toward type-1 effector
function, and markedly cytotoxic [54–56].
Moreover, recent findings pointed out a pathogenetic role
of TH17 cells in vitiligo [57–59].
Namely, a population of TH17 cells able to release the
cytokine IL-17 has been recently found in the epidermis of
active vitiligo skin [58, 59]. Accordingly, IL-17 levels have
been found increased in the serum and in lesional epi-
dermis of vitiligo patients [57].This cytokine is able to induce
the release of proinflammatory cytokines (namely, IL-1,
IL-6, TNF𝛼, TGF𝛽, GM-CSF, and prostaglandins) from
activated immune cells such as fibroblasts, keratinocytes,
endothelial cells, and macrophages [59]. This consequent
local cytokine network recruits and activates mononuclear
lymphocytes or neutrophils, which are strongly implicated
in vitiligo pathogenesis. In addition, in vitro studies showed
that human cultured melanocytes treated with IL-17A dis-
played a reduced melanin production, a downregulation of
the microphthalmia-associated transcription factor (MITF),
which is implicated in the transcription of key genes involved
in melanogenesis, and a reduced expression of the m-RNA
encoding for the antiapoptotic protein B cell lymphoma gene-
2 (BCL2), thus suggesting the unfavourable effects of IL-17A
on melanocyte function and survival [59].
Finally, a plethora of novel findings support the crucial
role of regulatory T cells (Tregs) in vitiligo pathogenesis
[60]. Indeed circulating Tregs, whose function is to main-
tain peripheral tolerance through the active suppression of
self-reactive T-cell activation and proliferation, have been
reported to be decreased in vitiligo patients, compared
to controls [61, 62]. Accordingly, a remarkable reduction
in the number of Tregs has been observed also in the
perilesional and lesional skin of vitiligo patients [63]. It is
noteworthy that besides a decrease of circulating Treg cells
number, patients affected by active vitiligo also display an
impaired Tregs function, as demonstrated by their altered
capacity to inhibit the proliferation of stimulated CD8+T cells
and their cytokine production [60]. Possibly, the impaired
cytokine network typical of vitiligo might contribute to the
reduction and the loss of function of Tregs. Both TGF
beta and IL 10 indeed, which are physiological inducers of
Tregs function and proliferation, have been found to be
decreased in active vitiligo lesions [8, 64, 65], thus leading to
an impaired peripheral tolerance. Future strategies for vitiligo
treatment will be probably targeted to improve Tregs number
and regulatory functions, as shown by recent promising
experiments conducted in mice [66].
Taken together, the abovementioned evidences thus sug-
gest the pathogenetic role of both humoral and cell mediated
immunity.
Concerning the epidemiological and clinical evidences of
an autoimmune theory of vitiligo, the frequent association
with organ-specific autoimmune disorders [1, 5, 43] and
a positive response to immunosuppressive treatments in
vitiligo patients [12, 67] are the most important proofs.
4. Interplay between Oxidative Stress and
Autoimmunity in Vitiligo
The role played by autoimmunity and oxidative stress in the
pathogenesis of vitiligo until now was considered as mutually
exclusive. Recent findings instead suggested that these two
mechanisms are both involved in the depigmentation process
and act in synergism [13]. In autoimmune disorders such as
vitiligo, the immune system develops a chronic inflammatory
milieu in which ROS accumulate and exert a toxic effect on
surrounding cells [13].
Structural or functional melanocytic proteins therefore
may be modified by acute and chronic oxidative stress,
possibly becoming neoantigens able to trigger autoreactive
reactions [68]. Hence, according to this new theory, autoim-
munity and oxidative stress interact in initiating and/or
amplifying the loss of melanocytes in vitiligo.
A recent paper [69] suggests that oxidative stress and
autoimmunity coexist in vitiligo butmight play different roles
in initiating or perpetrating vitiligo. Namely, in this case
control study, anti-melanocyte antibody levels, suggestive of
an autoimmune process, and lipid peroxidation levels, which
indeed indicate an oxidative stress, were evaluated in both
early onset and late duration vitiligo patients. Authors found
that lipid peroxidation levels were increased in patients with
early onset vitiligo, while, on the contrary, anti-melanocyte
antibodies were increased in long duration vitiligo patients
[69]. Therefore, oxidative stress rather than autoantibodies
might play a major role in initiating vitiligo [69]. Possibly, the
consequent accumulation of ROS might secondarily trigger
autoimmunity and precipitate the depigmenting process of
vitiligo, since ROS might alter the structure of protein
involved in melanogenesis, such as tyrosinase, making them
more antigenic.
5. Pathogenetic Interconnections at
the Basis of Vitiligo and Autoimmune
Thyroid Comorbidities
Patients with vitiligo have elevated frequencies of associated
autoimmune disorders and among them [70, 71] autoimmune
thyroid disorders (ATD) are the most frequently found
comorbidities [3].
ATD are a group of disease characterized by the presence
of autoantibodies directed against thyroglobulin, thyroper-
oxidase or thyroid-stimulating hormone receptor, which
are pivotal thyroid-specific molecules for the production
of thyroid hormones. Autoimmune thyroid disorders can
be associated or not with thyroid dysfunction. A recent
systematic review pointed out that the risk for vitiligo patients
to developATDdiseases is even higher (2.5 fold) compared to
nonvitiligo patients, while the risk to develop elevated thyroid
antibodies is more than 5-fold higher in vitiligo patients than
in nonvitiligo patients [3]. Accordingly, a screening of ATD is
recommended in vitiligo patients [3].
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A recent study performed by our working group [72] has
investigated the presence of an uncommon group of autoanti-
bodies directed against thyroid hormones (triiodothyronine
and/or thyroxine) (THAbs), in patients with vitiligo. THAbs
represent a class of thyroid autoantibodies showing a very low
prevalence in the general population [73, 74] but increased
in some thyroid and extra-thyroid autoimmune diseases
such as Hashimoto’s thyroiditis, Graves’ disease, primary
Sjo¨gren’s syndrome, or rheumatoid arthritis [75]. Even if their
pathogenetic role is still quite obscure, a study reported that
their presence in nonthyroid autoimmune diseases seem to
be predictive of overt ATD [75].
We showed that THAbs have a surprisingly elevated
prevalence in vitiligo, higher than in other disease investi-
gated so far, and significantly correlate with active vitiligo,
leukotrichia, disease duration, and thyroglobulin antibod-
ies positivity. All together, these results suggest a possible
pathogenic role of THAb in vitiligo [72].
As mentioned above, a chronic inflammatory milieu, as
can be found in vitiligo, can lead to local and systemic ROS
accumulation. To explain our findings, we suggest that ROS
increase might be toxic for thyroid, leading the release of
large amounts of thyroglobulin proteins that can be more
accessible to immune system attack [72].
At the same time, in patients with thyroid autoimmunity
increased ROS levels [76] have been demonstrated which
might contribute to modify tyrosinase or other melanogenic
proteins into neoantigens, leading to the appearance of
vitiligo.Thus melanocytic and thyroid systemmight interact,
creating a vicious cycle in which thyroid autoimmune pro-
cesses give rise to vitiligo lesions, and in turn vitiligo sustains
the formation of thyroid autoantibodies, such as THAbs [76].
We suggest that an important role in determining these
events might be played also by heavy metals, pollutants,
ionizing radiations, and other chemical substances [77] that
induce the production of ROS and are considered endocrine
disruptors [78]. These agents indeed are able to unfavorably
affect thyroid or other endocrine gland functions through a
wide range ofmolecular toxicmechanisms [78].Therefore, an
increased ROS accumulation due to environmental exposure
could induce modifications of both melanocytic structures
and thyroid proteins, leading to the frequently reported
association of vitiligo and thyroid diseases [77].
6. Conclusions
Overall, according to the evidences and theories discussed
above, we can state that vitiligo has complex pathogenesis in
which a pivotal role is played by oxidative stress and immune
system. A growing body of evidences indeed shows that
autoimmunity and oxidative stress interact andwork together
in creating a pathway finally able to determine melanocyte
loss. In this scenario thyroid autoimmunity, which was so
far considered simply as a comorbidity might instead play an
active and important role, possibly contributing to trigger and
maintain the depigmentation process of vitiligo.
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